NZ513529A - Spontaneously dispersible N-benzoyl staurosporine compositions - Google Patents

Spontaneously dispersible N-benzoyl staurosporine compositions

Info

Publication number
NZ513529A
NZ513529A NZ513529A NZ51352900A NZ513529A NZ 513529 A NZ513529 A NZ 513529A NZ 513529 A NZ513529 A NZ 513529A NZ 51352900 A NZ51352900 A NZ 51352900A NZ 513529 A NZ513529 A NZ 513529A
Authority
NZ
New Zealand
Prior art keywords
surfactant
composition
benzoylstaurosporine
benzoyl
pharmaceutical composition
Prior art date
Application number
NZ513529A
Other languages
English (en)
Inventor
Graham Paul Matthews
Barbara Haberlin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10847896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ513529(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NZ513529A publication Critical patent/NZ513529A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ513529A 1999-02-16 2000-02-14 Spontaneously dispersible N-benzoyl staurosporine compositions NZ513529A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9903547.9A GB9903547D0 (en) 1999-02-16 1999-02-16 Organic compounds
PCT/EP2000/001196 WO2000048571A1 (en) 1999-02-16 2000-02-14 Spontaneously dispersible n-benzoyl staurosporine compositions

Publications (1)

Publication Number Publication Date
NZ513529A true NZ513529A (en) 2003-10-31

Family

ID=10847896

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ513529A NZ513529A (en) 1999-02-16 2000-02-14 Spontaneously dispersible N-benzoyl staurosporine compositions

Country Status (34)

Country Link
US (3) US20020061873A1 (zh)
EP (1) EP1152750B1 (zh)
JP (2) JP5057610B2 (zh)
KR (2) KR100880859B1 (zh)
CN (1) CN100367930C (zh)
AR (2) AR022589A1 (zh)
AT (1) ATE430554T1 (zh)
AU (1) AU765776B2 (zh)
BR (1) BRPI0008228B8 (zh)
CA (1) CA2362277C (zh)
CL (1) CL2009001682A1 (zh)
CZ (1) CZ303979B6 (zh)
DE (1) DE60042151D1 (zh)
DK (1) DK1152750T3 (zh)
EC (1) ECSP083351A (zh)
ES (1) ES2326783T3 (zh)
GB (1) GB9903547D0 (zh)
HK (1) HK1045807B (zh)
HU (1) HUP0105364A3 (zh)
ID (1) ID30504A (zh)
IL (3) IL144512A0 (zh)
MY (1) MY128362A (zh)
NO (1) NO331232B1 (zh)
NZ (1) NZ513529A (zh)
PE (1) PE20001499A1 (zh)
PL (1) PL198330B1 (zh)
PT (1) PT1152750E (zh)
RU (1) RU2266121C2 (zh)
SI (1) SI1152750T1 (zh)
SK (1) SK286967B6 (zh)
TR (1) TR200102385T2 (zh)
TW (1) TWI240636B (zh)
WO (1) WO2000048571A1 (zh)
ZA (1) ZA200106677B (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
CA2439097C (en) * 2001-03-26 2010-10-12 Novartis Ag Pharmaceutical compositions
HUP0400038A3 (en) 2001-05-16 2007-05-29 Novartis Ag Combination comprising n-{5-[4-{-methyl-piperazino-methyl)-benzoylamino]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
CN1582150B (zh) * 2001-10-30 2011-09-07 诺瓦提斯公司 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
EP1531793A1 (en) * 2002-07-23 2005-05-25 Novartis AG Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
BRPI0714963A2 (pt) * 2006-08-16 2013-07-30 Novartis Ag processo de fabricaÇço de dispersÕes sàlidas de compostos terapÊuticos altamente cristalinos
FR2918566B1 (fr) 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
US20090155352A1 (en) * 2007-11-20 2009-06-18 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
EP2229936B1 (en) * 2009-03-09 2015-05-06 PharmaSol GmbH Nanonized testosterone formulations for improved bioavailability
WO2011000811A2 (en) * 2009-06-30 2011-01-06 Novartis Ag Organic compounds
CN102781425B (zh) * 2009-12-22 2014-08-13 利奥制药有限公司 含有维生素d类似物以及溶剂和表面活性剂混合物的皮肤用组合物
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
US9387446B2 (en) * 2011-09-22 2016-07-12 Ariel-University Research And Development Company Ltd. Emulsions and methods of making emulsions
RU2742650C2 (ru) * 2015-12-09 2021-02-09 Фосфейдженикс Лимитед Фармацевтический состав
JP6882321B2 (ja) 2015-12-09 2021-06-02 フォスファージニクス リミテッド 医薬製剤
NZ754168A (en) 2016-12-21 2024-08-30 Avecho Biotechnology Ltd Process for phosphorylating a complex alcohol
EP4058465A1 (en) 2019-11-14 2022-09-21 Cohbar Inc. Cxcr4 antagonist peptides

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4735939A (en) * 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
DE3824034C1 (zh) * 1988-07-15 1989-09-14 Gustav 7290 Freudenstadt De Memminger
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
CA2108266C (en) * 1991-04-19 2003-06-03 Albert J. Owen Convertible microemulsion formulations
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US6306421B1 (en) * 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
US5639474A (en) * 1993-07-01 1997-06-17 Hanmi Pharm. Ind., Ltd. Cyclosporin soft capsule composition
US5707648A (en) * 1993-11-17 1998-01-13 Lds Technologies, Inc. Transparent liquid for encapsulated drug delivery
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
US5599808A (en) * 1994-02-18 1997-02-04 Cephalon, Inc. Aqueous indolocarbazole solutions
JPH10501527A (ja) * 1994-06-01 1998-02-10 チバ−ガイギー アクチェンゲゼルシャフト 多重薬剤耐性細胞を抗腫瘍剤に対して感受性にするためのインドロカルバゾール誘導体
PE52896A1 (es) 1994-10-26 1996-12-12 Novartis Ag Composicion farmaceutica
GB2308545B (en) 1994-10-26 1999-06-02 Novartis Ag Pharmaceutical microemulsion preconcentrates
EP0711557A1 (de) * 1994-11-09 1996-05-15 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage
EP0733372A3 (de) * 1995-03-21 1998-05-20 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage für Nanosuspensionen
AU4491697A (en) 1996-09-27 1998-04-17 Trega Biosciences, Inc. Compositions of therapeutic agents suitable for oral administration
DE19641672A1 (de) 1996-10-10 1998-04-16 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen auf der Basis von ethylenoxidfreien und propylenoxidfreien Emulgatoren zur Herstellung von Mikroemulsionsgelen
US5827522A (en) 1996-10-30 1998-10-27 Troy Corporation Microemulsion and method
NZ314060A (en) 1997-01-13 1997-08-22 Bernard Charles Sherman Pharmaceutical microemulsion preconcentrate comprising cyclosporin dissolved in a solvent system comprising hydrophobic solvent(s) and surfactant(s)
GB2355195B (en) * 1997-01-30 2001-09-12 Novartis Ag Oil-free pharmaceutical compositions containing cyclosporin A
CA2294032A1 (en) 1997-07-29 1999-02-11 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
DE69823663T2 (de) 1997-07-29 2005-05-19 Pharmacia & Upjohn Co., Kalamazoo Selbstemulgierbare formulierung enthaltend lipophile verbindungen
US6346511B1 (en) * 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
AR013276A1 (es) 1998-07-31 2000-12-13 Panacea Biotec Ltd Composicion de ciclosporina transparente
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

Also Published As

Publication number Publication date
ZA200106677B (en) 2003-01-14
US20140056974A1 (en) 2014-02-27
US20020061873A1 (en) 2002-05-23
US8722664B2 (en) 2014-05-13
ECSP083351A (es) 2008-08-29
PL350556A1 (en) 2002-12-16
HUP0105364A3 (en) 2003-02-28
MY128362A (en) 2007-01-31
RU2266121C2 (ru) 2005-12-20
SK286967B6 (sk) 2009-08-06
IL192666A0 (en) 2009-02-11
CN1339963A (zh) 2002-03-13
TR200102385T2 (tr) 2002-09-23
US20080070897A1 (en) 2008-03-20
IL144512A (en) 2011-03-31
AR082579A2 (es) 2012-12-19
PL198330B1 (pl) 2008-06-30
PT1152750E (pt) 2009-08-07
GB9903547D0 (en) 1999-04-07
DE60042151D1 (de) 2009-06-18
AR022589A1 (es) 2002-09-04
BRPI0008228B8 (pt) 2021-05-25
IL144512A0 (en) 2002-05-23
NO331232B1 (no) 2011-11-07
KR100880859B1 (ko) 2009-01-30
EP1152750A1 (en) 2001-11-14
CZ20012931A3 (cs) 2001-11-14
BR0008228A (pt) 2001-10-30
KR20080064914A (ko) 2008-07-09
CL2009001682A1 (es) 2010-07-23
CZ303979B6 (cs) 2013-07-31
PE20001499A1 (es) 2001-01-12
HK1045807B (zh) 2008-12-05
NO20013964L (no) 2001-10-15
WO2000048571A1 (en) 2000-08-24
ATE430554T1 (de) 2009-05-15
CN100367930C (zh) 2008-02-13
CA2362277C (en) 2010-03-30
JP5057610B2 (ja) 2012-10-24
CA2362277A1 (en) 2000-08-24
ID30504A (id) 2001-12-13
ES2326783T3 (es) 2009-10-20
NO20013964D0 (no) 2001-08-15
AU765776B2 (en) 2003-10-02
JP2012111763A (ja) 2012-06-14
SI1152750T1 (sl) 2009-10-31
KR20010093281A (ko) 2001-10-27
AU3154200A (en) 2000-09-04
BRPI0008228B1 (pt) 2016-08-23
DK1152750T3 (da) 2009-08-24
TWI240636B (en) 2005-10-01
HK1045807A1 (en) 2002-12-13
JP2002537242A (ja) 2002-11-05
EP1152750B1 (en) 2009-05-06
US8575147B2 (en) 2013-11-05
HUP0105364A2 (hu) 2002-05-29
SK11722001A3 (sk) 2001-12-03

Similar Documents

Publication Publication Date Title
US8722664B2 (en) Spontaneously dispersible N-benzoyl staurosporine compositions
AU765935B2 (en) Substantially oil-free cyclosporin compositions
EP1082119B1 (en) Microemulsion preconcentrates containing a piperidine substance p antagonist
AU2005210134A1 (en) Microemulsion formulations comprising particular substance P antagonists
MXPA01008293A (en) Spontaneously dispersible n-benzoyl staurosporine compositions
ZA200006597B (en) Microemulsion preconcentrates containing a piperidine substance p antagonist.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 14 FEB 2020 BY CPA GLOBAL

Effective date: 20130117

EXPY Patent expired